Health and economic outcomes over 20 years with 3rd-generation ELISA.

All outcomes are relative to the status quo (approximately 1.18 million new infections over 20 years). MSM  =  men who have sex with men; IDU  =  injection drug user; 3G ELISA  =  third-generation enzyme linked immunosorbent assay; AHI  =  acute HIV infection; NAAT  =  nucleic acid amplification test; QALY  =  quality-adjusted life year; ICER  =  incremental cost-effectiveness ratio compared to the status quo or next best strategy for each risk group. *  =  weakly dominated strategy (this strategy is not on the cost-effectiveness frontier and is thus not economically efficient).

所有结局均以现状为参照基准（20年内约118万例新增感染病例）。MSM：男男性行为者（men who have sex with men）；IDU：注射毒品使用者（injection drug user）；3G ELISA：第三代酶联免疫吸附试验（third-generation enzyme linked immunosorbent assay）；AHI：急性HIV感染（acute HIV infection）；NAAT：核酸扩增试验（nucleic acid amplification test）；QALY：质量调整生命年（quality-adjusted life year）；ICER：针对各风险组别、与现状或次优策略相比的增量成本效果比（incremental cost-effectiveness ratio）。* 为弱占优策略（该策略未位于成本效果前沿线上，因此不具备经济有效性）。